A review of the coronavirus vaccine invented by the University of Oxford and the pharmaceutical company AstraZeneca in the United Kingdom found that the older the recipient, the higher his or her immune system. Europe’s drug regulator EMA said in a statement on Friday. The EMA says the safety of adults in the vaccine is even more important than the concerns that have been raised about the blood clotting barrier.
Meanwhile, a UK study found that taking the first dose of the Oxford-Astrageneca or Pfizer-Bioentech vaccine reduced the risk of corona infection by 75 per cent.
France 24 quoted AFP as saying that several countries had suspended the vaccination of the elderly as part of a precautionary measure against blood clots following the AstraZeneca vaccine. The European Commission has asked the European Pharmaceutical Agency (EMA) to look into the matter. In this context, EMA has published the results obtained by reviewing the data of AstraZeneca Ticker.
The Amsterdam-based EMA in the Netherlands said in a statement:
The statement said, “The benefits of the vaccine are higher for all adults than the concerns raised about the vaccine. However, in a few cases, there have been cases of low blood platelets and blood clots after vaccination.
The statement also said that one in every one lakh vaccine recipients had a rare case of blood clotting.
The statement further said, “The AstraZeneca vaccine is effective in preventing hospital admissions, intensive care unit (ICU) and covid-19 deaths.” The side effects of this vaccine are usually mild or moderate and get better within a few days. ‘
However, there was no clear evidence that women were more likely than men to have blood clots after being vaccinated with the AstraZeneca vaccine, the statement said.
Earlier, the BBC reported that a study in the United Kingdom found that the risk of developing covidosis decreased rapidly after taking the first dose of the AstraZeneca or Pfizer vaccine.
Research by The Office for National Statistics (ONS) and the University of Oxford says that the AstraZeneca or Pfizer vaccine works in the same way for all people over the age of 65. These vaccines have worked just as well in people with underlying health problems.
Studies have also shown that strong antibody reactions are developed in people of all ages after taking two doses of the vaccine. And after being vaccinated against Astrageneca or Pfizer, there has been some positive response from everyone. The effects of the corona vaccine on antibody production and disease resistance were two aspects of this study.
One study found that taking the first dose of the Oxford-Astrageneca or Pfizer-Bioentech vaccine reduced the risk of corona infection by 75 percent.
Those who were vaccinated between December last year and early April this year saw a 74 percent reduction in coronary heart disease, including symptoms, three weeks after vaccination. And asymptomatic corona infections decreased by 56 percent.
And those who took the second dose of Pfizer’s coronary vaccine had a 90 percent reduced risk of infection. However, it was not possible to give the same account in the case of AstraZeneca vaccine. Because of the late start of the AstraZeneca vaccination program, very few people have been able to take a second dose of this vaccine.